Weight Loss Peptides

Semaglutide is a GLP-1 receptor agonist with 94% sequence homology to human glucagon-like peptide-1. Used for weight management (Wegovy) and type 2 diabetes (Ozempic). Demonstrates significant effects on appetite regulation and glucose control.

Tirzepatide is a dual GIP/GLP-1 receptor agonist for weight management and type 2 diabetes. Marketed as Mounjaro (diabetes) and Zepbound (weight management). Outperforms semaglutide in head-to-head trials for both glucose control and weight loss.

Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks. Currently in Phase 3 development.

Liraglutide is a GLP-1 receptor agonist with 97% sequence homology to native GLP-1. FDA-approved as Victoza (diabetes) and Saxenda (weight management). Established efficacy and safety profile with extensive clinical data.

5-Amino-1MQ is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme linked to obesity and metabolic dysfunction. Research focuses on fat cell metabolism, weight loss, and reversing diet-induced obesity in preclinical models.

HGH Fragment 176-191 is a stabilized fragment of the C-terminal portion of human growth hormone (amino acids 176-191). It is the parent compound of AOD-9604. Research focuses on fat metabolism and lipolysis without the growth-promoting or diabetogenic effects of full GH.

AOD-9604 is a modified C-terminal fragment of human growth hormone (amino acids 176-191). Originally developed as an anti-obesity agent. Shows preclinical evidence for promoting fat metabolism without affecting blood sugar or growth.